The emergence of SARS-CoV-2 antibody escape mutations highlights the urgent need for
broadly neutralizing therapeutics. We previously identified a human monoclonal antibody …

Monoclonal antibodies and antibody cocktails are a promising therapeutic and prophylaxis
for coronavirus disease 2019 (COVID-19). However, ongoing evolution of severe acute …

The COVID-19 pandemic is now approaching 2 years old, with more than 440 million people
infected and nearly six million dead worldwide, making it the most significant pandemic …

The evolution of SARS-CoV-2 could impair recognition of the virus by human antibody-
mediated immunity. To facilitate prospective surveillance for such evolution, we map how …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the global
COVID-19 pandemic infecting more than 106 million people and causing 2.3 million deaths …

An outbreak of coronavirus disease 2019 (COVID-19),–, caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), has spread globally. Countermeasures are needed …

The global spread of SARS-CoV-2/COVID-19 is devastating health systems and economies
worldwide. Recombinant or vaccine-induced neutralizing antibodies are used to combat the …

Emerging variants of concern (VOCs) are threatening to limit the effectiveness of SARS-CoV-
2 monoclonal antibodies and vaccines currently used in clinical practice; broadly …

Administration of convalescent plasma or neutralizing monoclonal antibodies (mAbs) is a
potent therapeutic option for coronavirus disease 2019 (COVID-19) caused by severe acute …

The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) has resulted in an unprecedented public health …